Frankfurt, Germany

Gerhard J Ahne

This inventor holds 1 USPTO granted patent. Top assignee: Hoechst Aktiengesellschaft. Active years: 1997.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gerhard J Ahne: Innovator in Antiviral and Antiparasitic Compounds

Introduction

Gerhard J Ahne is a notable inventor based in Frankfurt, Germany. He has made significant contributions to the field of chemistry, particularly in the development of compounds with antiviral and antiparasitic properties. His work has implications for medical advancements and the treatment of various diseases.

Latest Patents

Ahne holds a patent for "Cycloalkyltriols containing cyclic substituents, processes and Cycloalkyltriols containing heterocyclic substituents." This patent includes compounds that demonstrate antiviral and antiparasitic action, specifically those containing cyclopentyl- and cyclohexyltriols with heterocyclic substituents. His innovative approach in this area has led to the creation of compounds represented by the formulae I and II, which have potential therapeutic applications.

Career Highlights

Gerhard J Ahne has been associated with Hoechst Aktiengesellschaft, a prominent company in the pharmaceutical and chemical sectors. His work at Hoechst has allowed him to focus on the synthesis and application of novel chemical compounds, contributing to the company's reputation for innovation in the industry.

Collaborations

Ahne has collaborated with notable colleagues, including Irvin Winkler and Heinz H Anel. These partnerships have fostered a collaborative environment that enhances research and development efforts in their respective fields.

Conclusion

Gerhard J Ahne's contributions to the field of chemistry, particularly through his patent on antiviral and antiparasitic compounds, highlight his role as an innovator. His work continues to influence the development of new therapeutic agents.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…